Bepranemab
Mid-stage
completed
completed
CT.gov grounded
Tau-directed antibody program that matters because Alzheimer's cannot stay a one-mechanism pipeline forever.
Program overview
- Mechanism
- anti-tau antibody
- Modality
- monoclonal antibody
- Phase
- Mid-stage
- Status
- completed
- Recruitment
- completed
- Confidence
- medium
- Watch priority
- 3
- Last verified
- 20 Apr 2026
Sponsor and trial identifiers
- Sponsor
- UCB
- Trial IDs
- NCT04867616
ClinicalTrials.gov exact matches: NCT04867616
Regions and recruitment
United States
Belgium
Canada
France
Germany
Italy
Netherlands
Poland
Spain
United Kingdom
Indication tags
Alzheimer's
tau
Milestones and catalysts
- Last milestone
- A serious tau-targeted Alzheimer's program with completed mid-stage work worth keeping in view.
- Next expected catalyst
- Whether tau-antibody follow-through survives the broader amyloid-dominated landscape.
Related pages
Disease hub
Alzheimer's disease hub
Disease-specific views with programs, mechanisms, and related context.
Related programs
Each card explains why it is here so you can read the overlap at a glance.
Approved / Late-stage
active
active, not recruiting
Late-stage anti-amyloid program with high strategic importance for the Alzheimer's treatment landscape.
- Mechanism
- anti-amyloid antibody
- Modality
- monoclonal antibody
- Next catalyst
- Further rollout, label evolution, and follow-up data.
- Last verified
- 20 Apr 2026
Approved / Late-stage
active
active, not recruiting
Anti-amyloid antibody program targeting plaque clearance in early Alzheimer's disease.
- Mechanism
- anti-amyloid antibody
- Modality
- monoclonal antibody
- Next catalyst
- Additional post-approval data and uptake signals.
- Last verified
- 20 Apr 2026
Mid-stage
active
active, not recruiting
A serious tau program that matters because the Alzheimer's field still needs credible combination therapy attempts.
- Mechanism
- anti-MTBR tau antibody
- Modality
- monoclonal antibody
- Next catalyst
- Whether the tau-plus-amyloid combination thesis produces a clearer signal than monotherapy tracks.
- Last verified
- 20 Apr 2026
Mid / Late-stage
active
active, not recruiting
Follow-on anti-amyloid program that could matter for the next wave of Alzheimer's competition.
- Mechanism
- anti-amyloid antibody
- Modality
- monoclonal antibody
- Next catalyst
- Recruitment updates and larger efficacy or safety read-throughs.
- Last verified
- 20 Apr 2026